会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明公开
    • RE-IIBP 및 RNF20 결합을 이용한 혈액암 치료제 스크리닝 방법
    • 使用RE-IIBP和RNF20结合的血液癌治疗的筛选方法
    • KR1020170088462A
    • 2017-08-02
    • KR1020160008080
    • 2016-01-22
    • 중앙대학교 산학협력단
    • 서상범박진우김기범김지영
    • G01N33/50G01N33/558G01N33/543
    • 본발명은 RE-IIBP 및 RNF20 결합을이용한혈액암치료제스크리닝방법에관한것으로서, 상세하게는 RE-IIBP 및 RNF20 결합을촉진하는후보약물을선별하는단계를포함하는혈액암치료제스크리닝방법을제공한다. 한편, 본발명자들은 RE-IIBP 및 RNF20 결합정도가증가하면 RE-IIBP의 H3K79 HMTase 활성을증가시키고, RE-IIBP-매개 MEIS1 전사를촉진하여혈액암세포사멸을증가시킨다는것을확인하였으므로, 상기 RE-IIBP 및 RNF20 결합정도가증가하면혈액암세포사멸을증가시키므로혈액암을치료할수 있는혈액암치료제스크리닝방법으로유용하게사용될수 있다.
    • 本发明是一种RE-IIBP和RNF20结合涉及使用相同的,特别是提供一种血液癌症筛选方法血癌筛选方法包括筛选候选药物促进接合RE-IIBP和RNF20的步骤。 在另一方面,本发明人已确定的增加程度hayeoteumeuro耦合RE-IIBP和RNF20增加RE-IIBP的H3K79 HMT酶的活性,并通过刺激RE-IIBP-介导的转移MEIS1增加血癌细胞死亡,对RE-IIBP 并且RNF20结合增加了血癌细胞死亡的程度,因此它可以有用地用作可以治疗血癌的血癌治疗的筛选方法。
    • 9. 发明公开
    • 히스톤 H3K9 메틸트랜스퍼라아제 G9a를 포함하는 골수증식 장애 예방 또는 치료용 약학 조성물
    • 包含HISTONE H3K9甲基转移酶G9A用于预防和治疗失语症的药物组合物
    • KR1020140046530A
    • 2014-04-21
    • KR1020120110200
    • 2012-10-04
    • 중앙대학교 산학협력단
    • 서상범김지영손혜주
    • A61K48/00A61P35/02A61P35/00
    • A61K38/45A61K48/005C12N9/1007G01N33/5008
    • The present invention provides a pharmaceutical composition for preventing or treating myeloproliferative disorders, comprising one or more materials selected from the group consisting of histone H3K9 methyltransferase G9a protein, a segment thereof, an activator thereof, an expression regulator thereof and a histone H3K9 methyltransferase G9a-encoding gene, and a pharmaceutically acceptable carrier. The histone H3K9 methyltransferase G9a according to the present invention inhibits the transcription of JAK2, and promotes ATRA-induced cell differentiation of the promyelocytic leukemia cell line HL-60 in a differentiation inducing therapy using all-trans retinoic acid (ATRA, tretinoin) as a vitamin inducer, instead of a bone fracture treatment, and thus is useful in the form of a cell therapeutic agent or a protein therapeutic agent for the treatment or prevention of diseases associated with JAK2 activation and mutation, specifically, myeloproliferative disorders.
    • 本发明提供一种预防或治疗骨髓增生性疾病的药物组合物,其包含选自组蛋白H3K9甲基转移酶G9a蛋白,其片段,其活化剂,其表达调节剂和组蛋白H3K9甲基转移酶G9a- 编码基因和药学上可接受的载体。 根据本发明的组蛋白H3K9甲基转移酶G9a抑制JAK2的转录,并且在使用全反式视黄酸(ATRA,维A酸)作为分化诱导疗法的促分化诱导疗法中促进早幼粒细胞白血病细胞系HL-60的ATRA诱导的细胞分化 维生素诱导剂,而不是骨折治疗,因此可用于治疗或预防与JAK2激活和突变有关的疾病,特别是骨髓增生性疾病的细胞治疗剂或蛋白质治疗剂的形式。